6533b823fe1ef96bd127e9a4
RESEARCH PRODUCT
GM-CSF in a Double-Blind Randomized Placebo-Controlled Trial in Therapy of Adult Patients with De Novo Acute Myeloid Leukemia
Hermann HeimpelKarin KolbeAlbrecht LindemannL. ChadidRoland MertelsmannDieter HoelzerU. NicolayParis S. MitrouGerhard HeilW. GausGernot SeipeltJ. FrischChristoph Hubersubject
Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industryPlacebo-controlled studyMyeloid leukemiaNeutropeniamedicine.diseaseGranulocyte colony-stimulating factorHaematopoiesisPharmacotherapyInternal medicineImmunologymedicineCytarabinebusinessmedicine.drugdescription
Despite the fact that 60%–70% of patients with de novo acute myeloblastic leukemia (AML) achieve a complete remission (CR) of the disease only about 20%–30% of the patients remain in long term remission and are probably cured [1,2]. These rather disappointing long-term results argue in favor of an even more intensive induction and post-remission therapy. This intention is, however, at time limited by therapy associated toxicity. Especially haematotoxicity seems to be the limiting factor in that patients with profound neutropenia are at high risk of developing fatal infectious complications [3]. In this context haematopoietic growth factors, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) have become of interest because of their ability to enhance regeneration of normal granulopoiesis and thereby reducing the rate of infectious complications [4, 5].
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1994-01-01 |